Add this topic to your myFT Digest for news straight to your inbox
Exscientia’s drug development programme secures funding from Gates Foundation
US pharma company agrees four-year deal with Oxford-based Exscientia
Molecule designed by machine to treat OCD developed in just 12 months
International Edition